Lonza has partnered with RION Biosciences to provide cGMP manufacturing and technical support for commercial-scale production of RION’s purified exosome product (PEP) drug substance. This milestone supports RION’s expanding pipeline across indications including tissue regeneration and immune-mediated diseases. Leveraging Lonza’s expertise in extracellular vesicle manufacturing will enable RION to meet clinical and future commercial demands, accelerating delivery of biologics-based therapies with regenerative and immunomodulatory properties.